HIV / AIDS in the News

Novel 1-pill regimen tamps down virus in older adults with HIV, study suggests - CIDRAP

 

HIV Treatment as Prevention: TASP Prevention of HIV/AIDS - HIV.gov

 

Preventing Sexual Transmission of HIV - hiv.gov

 

Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial - The Lancet

 

HIV & AIDS Trends and U.S. Statistics Overview - HIV.gov

 

Two transgender individuals suspected of deliberate HIV infection in Kazakhstan - AKIpress News Agency

 

Socioeconomic Factors Linked to COVID-19 Hospitalization in Women With HIV - Infectious Disease Advisor

 

Switch to DOR/ISL Maintains HIV-1 Virologic Suppression at 96 Weeks - Infectious Disease Advisor

 

Ibalizumab Yields Durable Virologic Suppression in Multidrug-Resistant HIV-1 - Infectious Disease Advisor

 

[Report] Alliance for Public Health: 25 Years of Lifesaving Impact. Four Years of Resilience in Wartime - European AIDS Treatment Group

 

Researchers uncover vulnerabilities in elusive HIV reservoir clones - News-Medical

 

[CROI 2026] MedPage Today: Semaglutide not linked to depression symptoms in people with HIV - European AIDS Treatment Group

 

[CROI 2026] MedPage Today: Study documents dramatic rise of throat cancer in people with HIV - European AIDS Treatment Group

 

[CROI 2026] AJMC: Sustained HIV viral suppression restores immune potential - European AIDS Treatment Group

 

Innovative Approaches Target HIV’s Final Strongholds - Bioengineer.org

 

Scientists confirm HIV capsid is a good drug target despite resistance - The Hindu

 

[CROI 2026] HIV i-Base: Islatravir PrEP didn’t protect against M184V mutation in macaque study - European AIDS Treatment Group

 

[CROI 2026] HIV i-Base: 11 mg dose selected for once-monthly MK-8527 for phase 3 PrEP studies - European AIDS Treatment Group

 

Very early ART may help children control HIV without treatment - Healio

 

[CROI 2026] aidsmap: Statin treatment reduces blood pressure in people with HIV, REPRIEVE trial shows - European AIDS Treatment Group

 

Community health project in Kenya and Uganda dramatically cuts new HIV infections - Science | AAAS

 

[CROI 2026] aidsmap: French study confirms efficacy of on-demand PrEP - European AIDS Treatment Group

 

[CROI 2026] aidsmap: The war on science: resisting and rebuilding at a crucial juncture - European AIDS Treatment Group

 

[CROI 2026] [Press release] ViiV Healthcare reports long-acting injectable Cabenuva effectively maintains viral suppression in adolescents living with HIV, with >97% preferring injections over daily oral treatment - European AIDS Treatment Group

 

US winds down health programmes after Mnangagwa rejects $367m deal - zimlive.com

 

Semaglutide Not Linked to Depression Symptoms in People With HIV - MedPage Today

 

GLP-1 Use in HIV, Innovations in STI Treatment Take Center Stage - The American Journal of Managed Care® (AJMC®)

 

Kenya-Uganda trial reduces HIV incidence by 70% in rural populations - Medical Xpress

 

Lab-grown reservoir cells aim at HIV's last strongholds - Medical Xpress

 

Kazakhstan - FHI 360